From capacity to capability: Five proofs for India’s pharma future
A contributed argument about the evidence behind pharmaceutical capability and the work that follows an announcement.
The published work
Medicines & AI
How medicines decisions become practical work, and how responsibility stays visible when software influences a choice.
Explore the full collection ↗AI and Accountability: When Does a Suggestion Become a Decision?
A conversation about judgement, responsibility and the point where a suggestion begins to influence action.
Approval is not access: Pilots’ real test is implementation
Varun examines the work between medicines approval, implementation and access.
Five questions to test whether an AI stack is truly under your control
Five questions about the control an organisation retains over the AI systems it uses.
India’s pharma quality reset will be won after the inspector leaves
A contributed perspective on pharmaceutical quality after the inspection itself has ended.
The publisher may require sign-in.
When three medicines numbers can all be right
Three figures can describe different parts of a medicines question. The article asks which denominator, period and task each one actually supports.
What feasibility research must prove
What makes a feasibility result useful, and which uncertainties should remain visible before a larger commitment.
From invention to adoption: the work between
The authority, evidence and practical work needed to carry an invention into use.
After NICE: making medicines access operational
The practical steps between a medicines recommendation and a service being ready to act on it.
A trade deal is not a patient pathway
Why a trade agreement needs implementation work before it can change a patient's route to treatment.
Why formulation and analytical science should shape medicines infrastructure
Why product behaviour, measurement and process understanding belong early in plans for medicines infrastructure.
Why Glasgow City Region is being evaluated for a proposed medicines campus
The questions behind evaluating a location for a proposed medicines campus, including demand and delivery.
What makes a science campus credible?
A science campus needs a purpose, users and an operating plan. This article examines those conditions.
From medicines intelligence to campus development
Varun explains how medicines intelligence and development questions inform a longer-term campus thesis.
Designing responsible AI and robotics for future medicines operations
A defined task, human authority and a meaningful comparison provide a starting point for responsible automation.
Why the India-UK trade deal now needs a five-gate implementation ledger
Commentary contributed by Varun to an article carrying Ross Law's publisher byline.
Five-Gate Framework Proposed for India-UK Pharmaceutical Trade Agreement Implementation
An AI-produced derivative of the Pharmaceutical Technology commentary, retained with its source relationship.
Original commentary ↗Business secures Innovate UK award for pharmaceutical manufacturing waste project
Publisher-written reporting on an Innovate UK award associated with a pharmaceutical manufacturing-waste project.
How we roll
A contribution about medicines expenditure and what different numbers describe.
NICE approval is not enough: why the UK’s next medicines challenge is operational delivery
A contributed perspective on the operational work needed after a medicines approval.
Digital Health Coffee Time Briefing
A news roundup that includes the company's funding record.
Stats US growth, Neuvior funds, Balmoral Comtec sold
A business-news roundup including the company's support announcement.
Glasgow pharmatech start-up backed by Scottish Enterprise
Reporting on Scottish Enterprise support for a defined company project.
NEUVIOR advances ZYLON programme following Innovate UK award
The research centre's account of initial feasibility work and the ZYLON programme.
Neuvior wins grant to tackle pharmaceutical sector waste with York scheme
Publisher-written reporting on a pharmaceutical-waste research project in York.
NEUVIOR Pharmaceuticals new sustainable drug trials
A local-news account of pharmaceutical manufacturing-waste research. Its original headline is retained.
Best-value biological medicines are the clearest near-term medicines productivity play in the NHS
A discussion of biological medicines, procurement and the work needed to interpret potential productivity opportunities.
NHS digital programmes do not fail on dashboards. They fail on deployment
Why the work around deployment can determine whether a digital programme becomes useful in practice.
The quarterly medicines leakage report every ICB should want in 2026/27
A proposal for examining medicines expenditure with explicit periods, denominators and local review.
The NHS has not finished the generic job
What generic-medicines data can and cannot establish about the remaining work in medicines productivity.
From pilot theatre to financial grip: how NHS CFOs should evaluate AI in medicines optimisation
A finance-focused argument for evaluating a defined medicines task against its existing approach.
The collection links to the original sources. Contribution labels distinguish bylined work, quoted views, reporting and appearances. Companion pieces and AI-produced derivatives retain their source relationships. Publisher access requirements apply.
Original dates appear where supplied. The collection was checked on 30 October 2026. Visit the press room for biographies, portraits and publication records.